LRRC14 as A Potential Drug Target for Various Diseases (G9684)

Target Name: LRRC14

NCBI ID: G9684

LRRC14

LRRC14 as A Potential Drug Target for Various Diseases

LRRC14 (KiAA0014) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidney. It is a member of the Kallikrein-related peptidases (KAPs) family, which includes a variety of pro-inflammatory cytokines and enzymes that play important roles in the regulation of inflammation and immune responses.

Recent studies have identified LRRC14 as a potential drug target for a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for drug development, as it is able to modulate the activity of multiple intracellular signaling pathways, including those involved in inflammation, angiogenesis, and cell survival.

One of the key mechanisms by which LRRC14 functions is through its ability to regulate the activity of integrins, which are proteins that interact with the cytoskeleton and play a central role in the distribution and movement of cells in various tissues. Integrins are involved in many different processes in the body, including cell adhesion, migration, and invasion, and they are often targeted by drugs that aim to disrupt their activity.

LRRC14 has been shown to play a negative role in the regulation of integrin function, which may make it an attractive target for drugs that are designed to modulate integrin activity. In addition, LRRC14 has been shown to play a role in the regulation of cell survival and angiogenesis, which may make it an attractive target for drugs that are designed to promote cell death or to inhibit cell proliferation.

The ability of LRRC14 to modulate multiple intracellular signaling pathways makes it an intriguing target for drug development. By targeting LRRC14, researchers hope to develop new treatments for a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and autoimmune disorders.

In conclusion, LRRC14 is a protein that has great potential as a drug target. Its unique structure and function make it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of LRRC14 in the regulation of intracellular signaling pathways and to identify the most effective treatments for diseases that are currently treated with limited success.

Protein Name: Leucine Rich Repeat Containing 14

Functions: Negatively regulates Toll-like receptor-mediated NF-kappa-B signaling by disrupting IKK core complex formation through interaction with IKBKB

The "LRRC14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets